General Information:

Id: 3,340
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Obesity - [OMIM]
Homo sapiens
male
article
Reference: Andrews RC et al.(2003) Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes J. Clin. Endocrinol. Metab. 88: 285-291 [PMID: 12519867]

Interaction Information:

Comment The principal active constituent of confectionary liquorice, glycyrrhetinic acid, and its hemisuccinate derivative, carbenoxolone, are potent inhibitors of both 11beta-HSD1 and its isoenzyme, 11beta-HSD2.
Formal Description
Interaction-ID: 30684

drug/chemical compound

Glycyrrhetinate

decreases_activity of

gene/protein

HSD11B1

Drugbank entries Show/Hide entries for HSD11B1
Comment The principal active constituent of confectionary liquorice, glycyrrhetinic acid, and its hemisuccinate derivative, carbenoxolone, are potent inhibitors of both 11beta-HSD1 and its isoenzyme, 11beta-HSD2.
Formal Description
Interaction-ID: 30690

drug/chemical compound

Glycyrrhetinate

decreases_activity of

gene/protein

HSD11B2

Drugbank entries Show/Hide entries for HSD11B2
Comment The principal active constituent of confectionary liquorice, glycyrrhetinic acid, and its hemisuccinate derivative, carbenoxolone, are potent inhibitors of both 11beta-HSD1 and its isoenzyme, 11beta-HSD2.
Formal Description
Interaction-ID: 30691

drug/chemical compound

Carbenoxolone

decreases_activity of

gene/protein

HSD11B1

Drugbank entries Show/Hide entries for Carbenoxolone or HSD11B1
Comment The principal active constituent of confectionary liquorice, glycyrrhetinic acid, and its hemisuccinate derivative, carbenoxolone, are potent inhibitors of both 11beta-HSD1 and its isoenzyme, 11beta-HSD2.
Formal Description
Interaction-ID: 30692

drug/chemical compound

Carbenoxolone

decreases_activity of

gene/protein

HSD11B2

Drugbank entries Show/Hide entries for Carbenoxolone or HSD11B2
Comment Six diet-controlled nonobese diabetic patients with hemoglobin A(1c) less than 8%, and six matched controls participated in a double-blind, cross-over comparison of carbenoxolone (100 mg every 8 h, orally, for 7 d) and placebo. Carbenoxolone had the expected effects of raising blood pressure and lowering plasma potassium. Carbenoxolone reduced total cholesterol in healthy subjects, but had no effect on other serum lipids or on cholesterol in diabetic patients.
Formal Description
Interaction-ID: 30693

drug/chemical compound

Carbenoxolone

increases_activity of

phenotype

hypertension

in healthy and diabetic lean males
Drugbank entries Show/Hide entries for Carbenoxolone
Comment Six diet-controlled nonobese diabetic patients with hemoglobin A(1c) less than 8%, and six matched controls participated in a double-blind, cross-over comparison of carbenoxolone (100 mg every 8 h, orally, for 7 d) and placebo. Carbenoxolone had the expected effects of raising blood pressure and lowering plasma potassium. Carbenoxolone reduced total cholesterol in healthy subjects, but had no effect on other serum lipids or on cholesterol in diabetic patients.
Formal Description
Interaction-ID: 30694

drug/chemical compound

Carbenoxolone

increases_activity of

in healthy and diabetic lean males
Drugbank entries Show/Hide entries for Carbenoxolone
Comment Six diet-controlled nonobese diabetic patients with hemoglobin A(1c) less than 8%, and six matched controls participated in a double-blind, cross-over comparison of carbenoxolone (100 mg every 8 h, orally, for 7 d) and placebo. Carbenoxolone had the expected effects of raising blood pressure and lowering plasma potassium. Carbenoxolone reduced total cholesterol in healthy subjects, but had no effect on other serum lipids or on cholesterol in diabetic patients.
Formal Description
Interaction-ID: 30695

drug/chemical compound

Carbenoxolone

decreases_quantity of

drug/chemical compound

Cholesterol

in healthy lean males
Drugbank entries Show/Hide entries for Carbenoxolone or Cholesterol
Comment Six diet-controlled nonobese diabetic patients with hemoglobin A(1c) less than 8%, and six matched controls participated in a double-blind, cross-over comparison of carbenoxolone (100 mg every 8 h, orally, for 7 d) and placebo. Carbenoxolone had the expected effects of raising blood pressure and lowering plasma potassium. Carbenoxolone reduced total cholesterol in healthy subjects, but had no effect on other serum lipids or on cholesterol in diabetic patients.
Formal Description
Interaction-ID: 30696

drug/chemical compound

Carbenoxolone

NOT affects_quantity of

drug/chemical compound

Cholesterol

in diabetic lean males
Drugbank entries Show/Hide entries for Carbenoxolone or Cholesterol
Comment Carbenoxolone did not affect the rate of glucose disposal or the suppression of free fatty acids during hyperinsulinemia. However, carbenoxolone reduced the glucose production rate during hyperglucagonemia in diabetic patients. This was attributable to reduced glycogenolysis rather than altered gluconeogenesis.
Formal Description
Interaction-ID: 30697

drug/chemical compound

Carbenoxolone

decreases_activity of

in diabetic lean males
Drugbank entries Show/Hide entries for Carbenoxolone
Comment Carbenoxolone did not affect the rate of glucose disposal or the suppression of free fatty acids during hyperinsulinemia. However, carbenoxolone reduced the glucose production rate during hyperglucagonemia in diabetic patients. This was attributable to reduced glycogenolysis rather than altered gluconeogenesis.
Formal Description
Interaction-ID: 30698

drug/chemical compound

Carbenoxolone

NOT affects_activity of

process

gluconeogenesis

Drugbank entries Show/Hide entries for Carbenoxolone